Company Description
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally.
The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium.
The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers’ off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage.
It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures.
In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators.
AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
| Country | United States |
| Founded | 1988 |
| IPO Date | May 27, 2004 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 632 |
| CEO | James Clemmer |
Contact Details
Address: 14 Plaza Drive Latham, New York 12110 United States | |
| Phone | 518 795 1400 |
| Website | angiodynamics.com |
Stock Details
| Ticker Symbol | ANGO |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0001275187 |
| CUSIP Number | 03475V101 |
| ISIN Number | US03475V1017 |
| Employer ID | 11-3146460 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James C. Clemmer | Chief Executive Officer, President and Director |
| Stephen A. Trowbridge | Executive Vice President and Chief Financial Officer |
| Lawrence T. Weiss | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality and Global Supply Chain |
| Laura Piccinini | Senior Vice President and GM of Cardiovascular and International |
| Saleem M. Cheeks | Vice President of Communications |
| Benjamin H. Davis | Senior Vice President of Business Development and Strategy |
| Marna I. Bronfen-Moore | Senior Vice President of Human Resources |
| Chad T. Campbell | Senior Vice President and GM of Oncology and Interventional Devices |
| Kim L. Seabury | Senior Vice President of Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 14, 2026 | 10-K | Annual Report |
| Jul 14, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| Apr 23, 2026 | 8-K | Current Report |
| Apr 2, 2026 | 10-Q | Quarterly Report |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 10, 2026 | SCHEDULE 13G | Filing |
| Feb 9, 2026 | SCHEDULE 13G | Filing |